Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD.

Massy ZA, Ferrières J, Bruckert E, Lange C, Liabeuf S, Velkovski-Rouyer M, Stengel B; CKD-REIN Collaborators.

Kidney Int Rep. 2019 Jul 30;4(11):1546-1554. doi: 10.1016/j.ekir.2019.07.014. eCollection 2019 Nov.

2.

[Evaluation and impact of "pregnancy" pharmaceutical pictograms among 281 women].

Bertrand D, Piedeloup I, Mattoug S, Liabeuf S, Gras-Champel V.

Therapie. 2019 Nov 25. pii: S0040-5957(19)30173-8. doi: 10.1016/j.therap.2019.11.001. [Epub ahead of print] French.

PMID:
31831186
3.

Calpain fosters the hyperexcitability of motoneurons after spinal cord injury and leads to spasticity.

Plantier V, Sanchez-Brualla I, Dingu N, Brocard C, Liabeuf S, Gackière F, Brocard F.

Elife. 2019 Dec 9;8. pii: e51404. doi: 10.7554/eLife.51404.

4.

Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study.

Rey A, Batteux B, Laville SM, Marienne J, Masmoudi K, Gras-Champel V, Liabeuf S.

Arthritis Res Ther. 2019 Nov 8;21(1):229. doi: 10.1186/s13075-019-2011-y.

5.

International variation in the management of mineral bone disorder in patients with chronic kidney disease: Results from CKDopps.

Liabeuf S, McCullough K, Young EW, Pisoni R, Zee J, Reichel H, Pecoits-Filho R, Port FK, Stengel B, Csomor PA, Metzger M, Robinson B, Massy ZA.

Bone. 2019 Dec;129:115058. doi: 10.1016/j.bone.2019.115058. Epub 2019 Sep 4.

PMID:
31493530
6.

Statin-associated myasthenia: A case report and literature review.

Gras-Champel V, Masmoudi I, Batteux B, Merle PE, Liabeuf S, Masmoudi K.

Therapie. 2019 Jul 26. pii: S0040-5957(19)30121-0. doi: 10.1016/j.therap.2019.07.004. [Epub ahead of print] No abstract available.

PMID:
31477339
7.

The drugs that mostly frequently induce gynecomastia: A national case - noncase study.

Batteux B, Llopis B, Muller C, Khouri C, Moragny J, Liabeuf S, Masmoudi K, Gras V; French National Network of Pharmacovigilance Centres.

Therapie. 2019 Jun 20. pii: S0040-5957(19)30098-8. doi: 10.1016/j.therap.2019.06.001. [Epub ahead of print]

PMID:
31471065
8.

Statin-induced myasthenia: A disproportionality analysis of the WHO's VigiBase pharmacovigilance database.

Gras-Champel V, Batteux B, Masmoudi K, Liabeuf S.

Muscle Nerve. 2019 Oct;60(4):382-386. doi: 10.1002/mus.26637. Epub 2019 Jul 29.

PMID:
31298743
9.

Serum concentration and vascular expression of adiponectin are differentially associated with the diabetic calcifying peripheral arteriopathy.

Aubert CE, Liabeuf S, Amouyal C, Kemel S, Lajat-Kiss F, Lacorte JM, Halbron M, Carlier A, Salem JE, Funck-Brentano C, Perisic Matic L, Witasp A, Stenvinkel P, Phan F, Massy ZA, Hartemann A, Bourron O.

Diabetol Metab Syndr. 2019 Apr 29;11:32. doi: 10.1186/s13098-019-0429-7. eCollection 2019.

10.

The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial.

Bennis Y, Cluet Y, Titeca-Beauport D, El Esper N, Ureña P, Bodeau S, Combe C, Dussol B, Fouque D, Choukroun G, Liabeuf S.

Toxins (Basel). 2019 May 17;11(5). pii: E279. doi: 10.3390/toxins11050279.

11.

Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients?

Lenglet A, Fabresse N, Taupin M, Gomila C, Liabeuf S, Kamel S, Alvarez JC, Drueke TB, Massy ZA.

Drugs. 2019 Jun;79(8):855-862. doi: 10.1007/s40265-019-01118-9.

PMID:
31062264
12.

Reply to "Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!" by Stamp et al.

Laville SM, Stengel B, Massy ZA, Liabeuf S.

Br J Clin Pharmacol. 2019 Jun;85(6):1380-1381. doi: 10.1111/bcp.13924. Epub 2019 Apr 13. No abstract available.

PMID:
30980562
13.

Guideline attainment and morbidity/mortality rates in a large cohort of European haemodialysis patients (EURODOPPS).

Liabeuf S, Sajjad A, Kramer A, Bieber B, McCullough K, Pisoni R, Caskey F, Combe C, Robinson BM, Jager KJ, Massy ZA.

Nephrol Dial Transplant. 2019 Dec 1;34(12):2105-2110. doi: 10.1093/ndt/gfz049.

PMID:
30938439
14.

Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients.

Fourdinier O, Schepers E, Metzinger-Le Meuth V, Glorieux G, Liabeuf S, Verbeke F, Vanholder R, Brigant B, Pletinck A, Diouf M, Burtey S, Choukroun G, Massy ZA, Metzinger L; European Uremic Toxin Work Group-EUTox.

Sci Rep. 2019 Mar 14;9(1):4477. doi: 10.1038/s41598-019-41101-8.

15.

Ischaemic colitis associated with intravitreal administration of aflibercept: A first case report.

Batteux B, Gras V, Mahboud Y, Liabeuf S, Bennis Y, Masmoudi K.

Br J Clin Pharmacol. 2019 Apr;85(4):845-848. doi: 10.1111/bcp.13853. Epub 2019 Feb 1.

PMID:
30610744
16.

Evolution of protein-bound uremic toxins indoxyl sulphate and p-cresyl sulphate in acute kidney injury.

Veldeman L, Vanmassenhove J, Van Biesen W, Massy ZA, Liabeuf S, Glorieux G, Vanholder R.

Int Urol Nephrol. 2019 Feb;51(2):293-302. doi: 10.1007/s11255-018-2056-x. Epub 2019 Jan 2.

PMID:
30604232
17.

From old uraemic toxins to new uraemic toxins: place of 'omics'.

Massy ZA, Liabeuf S.

Nephrol Dial Transplant. 2018 Oct 1;33(suppl_3):iii2-iii5. doi: 10.1093/ndt/gfy212. Review.

18.

Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort.

Laville SM, Metzger M, Stengel B, Jacquelinet C, Combe C, Fouque D, Laville M, Frimat L, Ayav C, Speyer E, Robinson BM, Massy ZA, Liabeuf S; Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) Study Collaborators.

Br J Clin Pharmacol. 2018 Dec;84(12):2811-2823. doi: 10.1111/bcp.13738. Epub 2018 Sep 24.

19.

Cognitive Impairments and Dysexecutive Behavioral Disorders in Chronic Kidney Disease.

Puy L, Bugnicourt JM, Liabeuf S, Desjardins L, Roussel M, Diouf M, Chillon JM, Choukroun G, Massy ZA, Godefroy O.

J Neuropsychiatry Clin Neurosci. 2018 Fall;30(4):310-317. doi: 10.1176/appi.neuropsych.18030047. Epub 2018 Jul 26.

PMID:
30045680
20.

Mild Intrauterine Hypoperfusion Leads to Lumbar and Cortical Hyperexcitability, Spasticity, and Muscle Dysfunctions in Rats: Implications for Prematurity.

Coq JO, Delcour M, Ogawa Y, Peyronnet J, Castets F, Turle-Lorenzo N, Montel V, Bodineau L, Cardot P, Brocard C, Liabeuf S, Bastide B, Canu MH, Tsuji M, Cayetanot F.

Front Neurol. 2018 Jun 15;9:423. doi: 10.3389/fneur.2018.00423. eCollection 2018.

21.

Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation.

Liabeuf S, Cheddani L, Massy ZA.

Toxins (Basel). 2018 Jun 5;10(6). pii: E229. doi: 10.3390/toxins10060229. Review.

22.

Risk profile, quality of life and care of patients with moderate and advanced CKD: The French CKD-REIN Cohort Study.

Stengel B, Metzger M, Combe C, Jacquelinet C, Briançon S, Ayav C, Fouque D, Laville M, Frimat L, Pascal C, Herpe YE, Morel P, Deleuze JF, Schanstra JP, Lange C, Legrand K, Speyer E, Liabeuf S, Robinson BM, Massy ZA.

Nephrol Dial Transplant. 2019 Feb 1;34(2):277-286. doi: 10.1093/ndt/gfy058.

PMID:
29635335
23.

The Association of Serum Free Light Chains With Mortality and Progression to End-Stage Renal Disease in Chronic Kidney Disease: Systematic Review and Individual Patient Data Meta-analysis.

Fraser SDS, Fenton A, Harris S, Shardlow A, Liabeuf S, Massy ZA, Burmeister A, Hutchison CA, Landray M, Emberson J, Kalra PA, Ritchie JP, Cockwell P, Taal MW.

Mayo Clin Proc. 2017 Nov;92(11):1671-1681. doi: 10.1016/j.mayocp.2017.08.021. Epub 2017 Nov 1. Review. Erratum in: Mayo Clin Proc. 2017 Dec;92 (12 ):1866. Kalra, Phil [corrected to Kalra, Phil A].

PMID:
29101935
24.

Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.

Liabeuf S, Ryckelynck JP, El Esper N, Ureña P, Combe C, Dussol B, Fouque D, Vanhille P, Frimat L, Thervet E, Mentaverri R, Prié D, Choukroun G; FRENCH Study collaborators.

Clin J Am Soc Nephrol. 2017 Dec 7;12(12):1930-1940. doi: 10.2215/CJN.03030317. Epub 2017 Oct 26.

25.

Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study.

Lenglet A, Liabeuf S, Esper NE, Brisset S, Mansour J, Lemaire-Hurtel AS, Mary A, Brazier M, Kamel S, Mentaverri R, Choukroun G, Fournier A, Massy ZA.

Nephrol Dial Transplant. 2017 Sep 1;32(9):1597. doi: 10.1093/ndt/gfx249. No abstract available.

PMID:
29059402
26.

Middle-Molecule Uremic Toxins and Outcomes in Chronic Kidney Disease.

Massy ZA, Liabeuf S.

Contrib Nephrol. 2017;191:8-17. doi: 10.1159/000479252. Epub 2017 Sep 14. Review.

PMID:
28910787
27.

Serum microRNAs are altered in various stages of chronic kidney disease: a preliminary study.

Brigant B, Metzinger-Le Meuth V, Massy ZA, McKay N, Liabeuf S, Pelletier M, Sallée M, M'Baya-Moutoula E, Paul P, Drueke TB, Burtey S, Metzinger L.

Clin Kidney J. 2017 Aug;10(4):578. doi: 10.1093/ckj/sfx068. Epub 2017 Jul 9.

28.

Activation of 5-HT2A Receptors Restores KCC2 Function and Reduces Neuropathic Pain after Spinal Cord Injury.

Sánchez-Brualla I, Boulenguez P, Brocard C, Liabeuf S, Viallat-Lieutaud A, Navarro X, Udina E, Brocard F.

Neuroscience. 2018 Sep 1;387:48-57. doi: 10.1016/j.neuroscience.2017.08.033. Epub 2017 Aug 30.

PMID:
28844001
29.

Prochlorperazine Increases KCC2 Function and Reduces Spasticity after Spinal Cord Injury.

Liabeuf S, Stuhl-Gourmand L, Gackière F, Mancuso R, Sanchez Brualla I, Marino P, Brocard F, Vinay L.

J Neurotrauma. 2017 Dec 15;34(24):3397-3406. doi: 10.1089/neu.2017.5152. Epub 2017 Sep 19.

PMID:
28747093
30.

Serum microRNAs are altered in various stages of chronic kidney disease: a preliminary study.

Brigant B, Metzinger-Le Meuth V, Massy ZA, McKay N, Liabeuf S, Pelletier M, Sallée M, M'Baya-Moutoula E, Paul P, Drueke TB, Burtey S, Metzinger L.

Clin Kidney J. 2017 Feb;10(1):30-37. doi: 10.1093/ckj/sfw060. Epub 2016 Jul 4. Retraction in: Clin Kidney J. 2017 Aug;10 (4):578.

31.

Higher parathyroid hormone levels are associated with increased below-the-knee arterial calcification in type 2 diabetes.

Mary A, Hartemann A, Brazier M, Aubert CE, Kemel S, Salem JE, Cluzel P, Liabeuf S, Massy Z, Mentaverri R, Bourron O, Kamel S.

Diabetes Metab. 2018 Jun;44(3):305-308. doi: 10.1016/j.diabet.2017.04.008. Epub 2017 Jun 8. No abstract available.

PMID:
28602488
32.

Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients.

Mary A, Hartemann A, Liabeuf S, Aubert CE, Kemel S, Salem JE, Cluzel P, Lenglet A, Massy ZA, Lalau JD, Mentaverri R, Bourron O, Kamel S.

Cardiovasc Diabetol. 2017 Feb 15;16(1):24. doi: 10.1186/s12933-017-0509-7.

33.

Attainment of guideline targets in EURODOPPS haemodialysis patients: are differences related to a country's healthcare expenditure and nephrologist workforce?

Liabeuf S, Van Stralen KJ, Caskey F, Tentori F, Pisoni RL, Sajjad A, Jager KJ, Massy ZA.

Nephrol Dial Transplant. 2017 Oct 1;32(10):1737-1749. doi: 10.1093/ndt/gfw409.

34.

The drugs that mostly frequently induce acute kidney injury: a case - noncase study of a pharmacovigilance database.

Pierson-Marchandise M, Gras V, Moragny J, Micallef J, Gaboriau L, Picard S, Choukroun G, Masmoudi K, Liabeuf S; French National Network of Pharmacovigilance Centres.

Br J Clin Pharmacol. 2017 Jun;83(6):1341-1349. doi: 10.1111/bcp.13216. Epub 2017 Mar 14.

35.

N-methyl-2-pyridone-5-carboxamide (2PY)-Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin.

Lenglet A, Liabeuf S, Bodeau S, Louvet L, Mary A, Boullier A, Lemaire-Hurtel AS, Jonet A, Sonnet P, Kamel S, Massy ZA.

Toxins (Basel). 2016 Nov 15;8(11). pii: E339. Review.

36.

Protein-bound toxins: has the Cinderella of uraemic toxins turned into a princess?

Liabeuf S, Villain C, Massy ZA.

Clin Sci (Lond). 2016 Dec 1;130(23):2209-2216. Review.

PMID:
27799624
37.

Adaptation and validation of an adverse drug reaction preventability score for bleeding due to vitamin K antagonists.

Liabeuf S, Masmoudi K, Scailteux LM, Moragny J, Masson H, Brnet-Dufour V, Andrejak M, Gras-Champel V.

Medicine (Baltimore). 2016 Sep;95(39):e4762. doi: 10.1097/MD.0000000000004762.

38.

[Vascular calcifications, the hidden side effects of vitamin K antagonists].

Bennis Y, Vengadessane S, Bodeau S, Gras V, Bricca G, Kamel S, Liabeuf S.

Therapie. 2016 Sep;71(4):355-63. doi: 10.1016/j.therap.2015.12.004. Epub 2016 Feb 4. Review. French.

PMID:
27203170
39.

Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study.

Lenglet A, Liabeuf S, El Esper N, Brisset S, Mansour J, Lemaire-Hurtel AS, Mary A, Brazier M, Kamel S, Mentaverri R, Choukroun G, Fournier A, Massy ZA.

Nephrol Dial Transplant. 2017 May 1;32(5):870-879. doi: 10.1093/ndt/gfw042.

PMID:
27190329
40.

Cleavage of Na(+) channels by calpain increases persistent Na(+) current and promotes spasticity after spinal cord injury.

Brocard C, Plantier V, Boulenguez P, Liabeuf S, Bouhadfane M, Viallat-Lieutaud A, Vinay L, Brocard F.

Nat Med. 2016 Apr;22(4):404-11. doi: 10.1038/nm.4061. Epub 2016 Mar 14.

PMID:
26974309
41.

Levels of Indoxyl Sulfate in Kidney Transplant Patients, and the Relationship With Hard Outcomes.

Liabeuf S, Desjardins L, Massy ZA, Brazier F, Westeel PF, Mazouz H, Titeca-Beauport D, Diouf M, Glorieux G, Vanholder R, Jaureguy M, Choukroun G.

Circ J. 2016;80(3):722-30. doi: 10.1253/circj.CJ-15-0949. Epub 2016 Feb 4.

42.

Risk Factors for Bleeding in Hospitalized at Risk Patients With an INR of 5 or More Treated With Vitamin K Antagonists.

Liabeuf S, Scaltieux LM, Masmoudi K, Roussel B, Moragny J, Andrejak M, Gras-Champel V.

Medicine (Baltimore). 2015 Dec;94(52):e2366. doi: 10.1097/MD.0000000000002366.

43.

The Addition of Vascular Calcification Scores to Traditional Risk Factors Improves Cardiovascular Risk Assessment in Patients with Chronic Kidney Disease.

Liabeuf S, Desjardins L, Diouf M, Temmar M, Renard C, Choukroun G, Massy ZA.

PLoS One. 2015 Jul 16;10(7):e0131707. doi: 10.1371/journal.pone.0131707. eCollection 2015.

44.

[Biomarkers of vascular calcifications: what are analytical limits to apply "research-grade" diagnostic kits into daily practice?].

Bargnoux AS, Arnaud J, Cavalier É, Piéroni L, Kamel S, Prié D, Souberbielle JC, Liabeuf S, Cristol JP; Groupe de Travail Mixte SFBC SN Biomarqueurs des Calcifications Vasculaires Au Cours de L'insuffisance Rénale Chronique.

Ann Biol Clin (Paris). 2015 May-Jun;73(3):323-32. doi: 10.1684/abc.2015.1043. Review. French.

45.

[Cardiovascular calcification inhibitors].

Liabeuf S, Delanaye P, Cavalier É, Guérin A, Kamel S, Massy ZA; Groupe de travail Biomarqueurs des calcifications vasculaires de la SFBC et de la Société de néphrologie.

Ann Biol Clin (Paris). 2015 May-Jun;73(3):315-22. doi: 10.1684/abc.2015.1047. Review. French.

46.

[Pathophysiological mechanisms of vascular calcification].

Hénaut L, Mentaverri R, Liabeuf S, Bargnoux AS, Delanaye P, Cavalier É, Cristol JP, Massy Z, Kamel S; Groupe de Travail Biomarqueurs des Calcifications Vasculaires de la SFBC et de la Société de Néphrologie.

Ann Biol Clin (Paris). 2015 May-Jun;73(3):271-87. doi: 10.1684/abc.2015.1044. Review. French.

47.

In geriatric patients, delirium symptoms are related to the anticholinergic burden.

Naja M, Zmudka J, Hannat S, Liabeuf S, Serot JM, Jouanny P.

Geriatr Gerontol Int. 2016 Apr;16(4):424-31. doi: 10.1111/ggi.12485. Epub 2015 May 8.

PMID:
25952295
48.

Association of advanced age with concentrations of uraemic toxins in CKD.

Rroji M, Eloot S, Dhondt A, Van Biesen W, Glorieux G, Neirynck N, Vandennoortgate N, Liabeuf S, Massy Z, Vanholder R.

J Nephrol. 2016 Feb;29(1):81-91. doi: 10.1007/s40620-015-0195-z. Epub 2015 Apr 10.

PMID:
25857296
49.

[The matrix-gla protein awakening may lead to the demise of vascular calcification].

Delanaye P, Liabeuf S, Bouquegneau A, Cavalier É, Massy ZA.

Nephrol Ther. 2015 Jul;11(4):191-200. doi: 10.1016/j.nephro.2014.12.003. Epub 2015 Mar 17. Review. French.

PMID:
25794931
50.

Erratum: Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein.

Liabeuf S, Bourron O, Vemeer C, Theuwissen E, Magdeleyns E, Aubert CE, Brazier M, Mentaverri R, Hartemann A, Massy ZA.

Cardiovasc Diabetol. 2015 Jan 24;14:9. doi: 10.1186/s12933-014-0164-1. No abstract available.

Supplemental Content

Loading ...
Support Center